These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31056650)

  • 1. Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome.
    Dubacher N; Münger J; Gorosabel MC; Crabb J; Ksiazek AA; Caspar SM; Bakker ENTP; van Bavel E; Ziegler U; Carrel T; Steinmann B; Zeisberger S; Meienberg J; Matyas G
    Cardiovasc Res; 2020 Feb; 116(2):457-465. PubMed ID: 31056650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular Ehlers-Danlos syndrome: can the beneficial effect of celiprolol be extrapolated to bisoprolol?
    Gorosabel MC; Dubacher N; Meienberg J; Matyas G
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):199-200. PubMed ID: 31693161
    [No Abstract]   [Full Text] [Related]  

  • 3. Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome.
    Baderkhan H; Wanhainen A; Stenborg A; Stattin EL; Björck M
    Eur J Vasc Endovasc Surg; 2021 Feb; 61(2):326-331. PubMed ID: 33223285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome.
    Briest W; Cooper TK; Tae HJ; Krawczyk M; McDonnell NB; Talan MI
    J Pharmacol Exp Ther; 2011 Jun; 337(3):621-7. PubMed ID: 21363928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline, prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome.
    Tae HJ; Marshall S; Zhang J; Wang M; Briest W; Talan MI
    J Pharmacol Exp Ther; 2012 Oct; 343(1):246-51. PubMed ID: 22815532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome.
    Yang HH; Kim JM; Chum E; van Breemen C; Chung AW
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):305-312.e2. PubMed ID: 20189193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploinsufficiency of the murine Col3a1 locus causes aortic dissection: a novel model of the vascular type of Ehlers-Danlos syndrome.
    Smith LB; Hadoke PW; Dyer E; Denvir MA; Brownstein D; Miller E; Nelson N; Wells S; Cheeseman M; Greenfield A
    Cardiovasc Res; 2011 Apr; 90(1):182-90. PubMed ID: 21071432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
    Ong KT; Perdu J; De Backer J; Bozec E; Collignon P; Emmerich J; Fauret AL; Fiessinger JN; Germain DP; Georgesco G; Hulot JS; De Paepe A; Plauchu H; Jeunemaitre X; Laurent S; Boutouyrie P
    Lancet; 2010 Oct; 376(9751):1476-84. PubMed ID: 20825986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II promotes thoracic aortic dissections and ruptures in Col3a1 haploinsufficient mice.
    Faugeroux J; Nematalla H; Li W; Clement M; Robidel E; Frank M; Curis E; Ait-Oufella H; Caligiuri G; Nicoletti A; Hagege A; Messas E; Bruneval P; Jeunemaitre X; Bergaya S
    Hypertension; 2013 Jul; 62(1):203-8. PubMed ID: 23630948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative therapeutic strategies for preventing aortic rupture in a mouse model of vascular Ehlers-Danlos syndrome.
    Legrand A; Guery C; Faugeroux J; Fontaine E; Beugnon C; Gianfermi A; Loisel-Ferreira I; Verpont MC; Adham S; Mirault T; Hadchouel J; Jeunemaitre X
    PLoS Genet; 2022 Mar; 18(3):e1010059. PubMed ID: 35245290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-institutional experience in the aortic and arterial pathology in individuals with genetically confirmed vascular Ehlers-Danlos syndrome.
    Shalhub S; Byers PH; Hicks KL; Charlton-Ouw K; Zarkowsky D; Coleman DM; Davis FM; Regalado ES; De Caridi G; Weaver KN; Miller EM; Schermerhorn ML; Shean K; Oderich G; Ribeiro M; Nishikawa C; Behrendt CA; Debus ES; von Kodolitsch Y; Powell RJ; Pepin M; Milewicz DM; Lawrence PF; Woo K
    J Vasc Surg; 2019 Nov; 70(5):1543-1554. PubMed ID: 31126764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome.
    Yang HH; Kim JM; Chum E; van Breemen C; Chung AW
    Br J Pharmacol; 2009 Nov; 158(6):1503-12. PubMed ID: 19814725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade.
    Kuang SQ; Geng L; Prakash SK; Cao JM; Guo S; Villamizar C; Kwartler CS; Peters AM; Brasier AR; Milewicz DM
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2172-9. PubMed ID: 23868934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice.
    Ren P; Wu D; Appel R; Zhang L; Zhang C; Luo W; Robertson AAB; Cooper MA; Coselli JS; Milewicz DM; Shen YH; LeMaire SA
    J Am Heart Assoc; 2020 Apr; 9(7):e014044. PubMed ID: 32223388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome.
    Xiong W; Knispel RA; Dietz HC; Ramirez F; Baxter BT
    J Vasc Surg; 2008 Jan; 47(1):166-72; discussion 172. PubMed ID: 18178469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications.
    Beridze N; Frishman WH
    Cardiol Rev; 2012; 20(1):4-7. PubMed ID: 22143279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study.
    Frank M; Adham S; Seigle S; Legrand A; Mirault T; Henneton P; Albuisson J; Denarié N; Mazzella JM; Mousseaux E; Messas E; Boutouyrie P; Jeunemaitre X
    J Am Coll Cardiol; 2019 Apr; 73(15):1948-1957. PubMed ID: 30999998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical artery dissections and type A aortic dissection in a family with a novel missense COL3A1 mutation of vascular type Ehlers-Danlos syndrome.
    Makrygiannis G; Loeys B; Defraigne JO; Sakalihasan N
    Eur J Med Genet; 2015 Nov; 58(11):634-6. PubMed ID: 26497932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable cellular signaling events mediate vascular pathology in vascular Ehlers-Danlos syndrome.
    Bowen CJ; Calderón Giadrosic JF; Burger Z; Rykiel G; Davis EC; Helmers MR; Benke K; Gallo MacFarlane E; Dietz HC
    J Clin Invest; 2020 Feb; 130(2):686-698. PubMed ID: 31639107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.